Clinical Trials Logo

Alzheimer Disease clinical trials

View clinical trials related to Alzheimer Disease.

Filter by:

NCT ID: NCT00219232 Completed - Alzheimer's Disease Clinical Trials

An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

Start date: February 2003
Phase: Phase 3
Study type: Interventional

The goal of this research study is to evaluate, in the open-label extension phase, the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease

NCT ID: NCT00216593 Completed - Alzheimer Disease Clinical Trials

Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study

Start date: December 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the effectiveness and safety of galantamine hydrobromide treatment in patients with severe Alzheimer's disease.

NCT ID: NCT00216515 Completed - Alzheimer Disease Clinical Trials

The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type

Start date: March 2004
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the efficacy of galantamine on the attention of patients with Alzheimer's Disease, how an improvement of attention of Alzheimer's Disease patients affects their activities of daily living, and the global benefit of galantamine.

NCT ID: NCT00216502 Completed - Alzheimer Disease Clinical Trials

A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease

Start date: August 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term efficacy and safety of galantamine in patients with Alzheimer's disease.

NCT ID: NCT00211159 Completed - Alzheimer's Disease Clinical Trials

OmegAD (Omega-3 and Alzheimer's Disease)

Start date: December 2000
Phase: N/A
Study type: Interventional

Memory loss and difficulties with thinking associated with Alzheimer's disease (AD) may be due to a deficiency in the brain of a fatty acid named DHA. The aim of this trial is to see if dietary supplementation with a preparation, rich in DHA, will halt cognitive impairment in AD patients

NCT ID: NCT00208819 Completed - Alzheimer Disease Clinical Trials

A Comparison of Two Standard Therapies in the Management of Dementia With Agitation

Start date: September 2003
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether an antipsychotic medication alone or an antipsychotic medication in combination with divalproex is the most effective and safest way to treat agitation in elderly patients with dementia.

NCT ID: NCT00205179 Completed - Alzheimer's Disease Clinical Trials

Alzheimer's Disease: Potential Benefit of Isoflavones

Start date: January 2005
Phase: Phase 2
Study type: Interventional

The purpose of this pilot study is to evaluate the potential effects of soy isoflavone supplements on cognitive function for men and women with Alzheimer's Disease (AD). Preliminary studies evaluating the effects of soy supplements on memory in cognitively healthy older adults have yielded promising results that are now being evaluated in patients with AD. It is hypothesized that isoflavone supplements will ameliorate cognitive declines for older adults diagnosed with Alzheimer's disease, when compared to subjects on placebo.

NCT ID: NCT00203359 Completed - Alzheimer's Disease Clinical Trials

TNF-Alpha Inhibition for Treatment of Alzheimer's Disease

Start date: September 2004
Phase: Phase 1
Study type: Interventional

It is widely believed that inflammation contributes to the pathogenesis of AD. TNF has been implicated in both AD and neurological inflammation. Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD.

NCT ID: NCT00203320 Completed - Alzheimer's Disease Clinical Trials

TNF-Alpha Inhibition for Treatment of Alzheimer's Disease

Start date: April 2005
Phase: Phase 1
Study type: Interventional

It is widely believed that inflammation contributes to the pathogenesis of AD. TNF has been implicated in both AD and neurological inflammation. Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD.

NCT ID: NCT00202124 Completed - Alzheimer's Disease Clinical Trials

Double Blind Study of Trp01 in Patients With Alzheimer's Disease

Start date: April 2001
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether tryptophan is effective in the treatment of mild to moderate Alzheimer's Disease (AD).